Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Clovis Oncology Inc CLVSQ

Healthcare Biotechnology
Clovis Oncology, Inc. is a biopharmaceutical company. The Company is focused on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe and additional international markets. Its segments include U.S. and ex-U.S. Its product, Rubraca, is an oral small molecule inhibitor of poly ADP-ribose polymerase (PARP) marketed in the United States for two indications... see more

Recent & Breaking News (PINL:CLVSQ)

Clovis Oncology Receives Breakthrough Therapy Designation for CO-1686 for the Treatment of Second-line EGFR Mutant Non-small Cell Lung Cancer (NSCLC) in Patients with the T790M Mutation

Business Wire May 19, 2014

Clovis Oncology Announces Clinical Data to Be Presented at 2014 ASCO Annual Meeting

Business Wire May 14, 2014

Clovis Oncology Announces First Quarter 2014 Operating Results

Business Wire May 8, 2014

Clovis Oncology to Announce First Quarter 2014 Financial Results and Host Webcast Conference Call on May 8

Business Wire April 28, 2014

Foundation Medicine and Clovis Oncology Expand Collaboration to Develop Novel Companion Diagnostic for Rucaparib in Ovarian Cancer

Business Wire April 3, 2014

Clovis Oncology's CO-1686 Demonstrates Compelling Clinical Activity and Progression-free Survival (PFS) in Updated Phase 1 Study Results in Patients with Non-small Cell Lung Cancer (NSCLC)

Business Wire March 27, 2014

Clovis Investors Cheer Trials, Shrug Off Larger Losses

Equities.com February 28, 2014

Clovis Oncology Announces 2013 Operating Results and Expands CO-1686 Development Program

Business Wire February 27, 2014

Clovis Oncology to Announce Fourth Quarter/Year End 2013 Financial Results and Host Webcast Conference Call on February 27

GlobeNewswire February 18, 2014

Clovis Oncology to Present at the 2014 Leerink Global Healthcare Conference

Business Wire February 6, 2014

Clovis Oncology Announces 2014 Objectives and Financial Guidance

Business Wire January 13, 2014

Clovis Oncology to Present at the 32nd Annual J.P. Morgan Healthcare Conference

Business Wire January 6, 2014

Clovis Oncology Announces CO-1686 Clinical Data Accepted as Oral Presentation at 2014 European Lung Cancer Conference

Business Wire December 23, 2013

Clovis Oncology Announces Sale of Shares of Common Stock by Selling Stockholders

Business Wire December 3, 2013

Clovis Oncology Announces Proposed Secondary Offering of Shares of Common Stock by Selling Stockholders

Business Wire December 2, 2013

Clovis Oncology Acquires EOS (Ethical Oncology Science) S.p.A. to Gain Rights to Lucitanib, a Unique Dual-Selective Phase II FGFR/VEGFR Inhibitor

Business Wire November 19, 2013

Clovis Oncology to Present at the Credit Suisse Annual Healthcare Conference

Business Wire November 5, 2013

Clovis Oncology Announces Third Quarter 2013 Operating Results

Business Wire October 31, 2013

Clovis Oncology Announces First Patient Enrolled in ARIEL2 Study of Rucaparib in Ovarian Cancer

Business Wire October 30, 2013

QIAGEN Reports Third Quarter 2013 Results

PR Newswire October 29, 2013